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ype 2 diabetes is characterized by a deﬁcit in
-cell mass, impaired insulin secretion in re-
sponse to various stimuli (1–3), as well as a
variable extent of insulin resistance (4). More
speciﬁcally, regarding -cell function, a signiﬁcant reduc-
tion of the incretin effect, i.e., the postprandial augmenta-
tion of insulin secretion by gut hormones, has been
described in patients with type 2 diabetes (5). Thus, while
the two incretin hormones gastric inhibitory polypeptide
(glucose-dependent insulinotopic polypeptide [GIP]) and
glucagon-like peptide 1 (GLP-1) are held responsible for
50–70% of the postprandial insulin responses in healthy
individuals (6), their contribution to the overall insulin
responses after oral glucose ingestion may amount to
20% in patients with type 2 diabetes (5,7). The reasons
underlying the loss of incretin activity in type 2 diabetes
are still incompletely understood. The present article
reviews the available evidence regarding disturbances in
the enteroinsular axis in patients with type 2 diabetes and
provides possible explanations for their etiologies, focus-
ing on the personal experience of the authors.
Secretion of incretin hormones in patients with type
2 diabetes. Because the incretin effect has been related to
the secretion and insulinotropic action of GIP and GLP-1
(8,9), it was obvious to compare these parameters be-
tween patients with type 2 diabetes and healthy control
subjects: Regarding the secretion of GIP, elevated, normal,
and reduced plasma levels have been described in patients
with type 2 diabetes (10–15). However, taking together all
the evidence available, the secretion of GIP appears to be
relatively unchanged in type 2 diabetic patients. For GLP-1
release, the case is even more complex. Several studies
have reported signiﬁcant reductions in GLP-1 levels after
mixed meal ingestion in patients with type 2 diabetes
(10,16,17). In addition, one study has found minor impair-
ments in GLP-1 levels in individuals with impaired glucose
tolerance (IGT) (16). However, upon more careful evalu-
ation, the defects in GLP-1 secretion in these patients with
type 2 diabetes were only found 2–3 h after meal
ingestion, whereas GLP-1 levels were rather unaltered in
the immediate postprandial period. Thus, the observed
impairments in GLP-1 release do not seem to coincide with
the alterations in insulin secretion typically found in
patients with type 2 diabetes. Furthermore, these reports
are contrasted by a number of other studies showing
normal GLP-1 responses in type 2 diabetic patients com-
pared with healthy individuals (11,18–20). Overall, GLP-1
concentrations appear to be highly variable between indi-
viduals, both with and without type 2 diabetes, mean
values being relatively normal in most groups with type 2
diabetes (18), suggesting that impaired GLP-1 release is
not a typical prerequisite for the development of the
disease (21). Figure 1 depicts the integrated GLP-1 levels
after oral glucose ingestion in relation to the respective
glucose concentrations in the fasting state and 120 min
after oral glucose ingestion in 48 individuals with different
degrees of oral glucose tolerance (11).
Insulinotropic effect of incretin hormones in type 2
diabetes. The relatively normal secretion of GIP and
GLP-1 is contrasted by their diminished activity in patients
with type 2 diabetes. In the case of GLP-1, the insulino-
tropic activity is usually referred to as being largely
preserved in patients with type 2 diabetes, which has led to
the broad utilization of its glucose-lowering potential in
the pharmacotherapy of type 2 diabetes (22). However,
upon careful examination, the amount of insulin released
in response to a supra-physiological GLP-1 infusion during
hyperglycemic clamp conditions has also been found to be
reduced by 29% compared with healthy control subjects
(23). Furthermore, studies applying a graded glucose
infusion protocol have demonstrated a signiﬁcant impair-
ment in the -cell responsiveness to the combined admin-
istration of GLP-1 and glucose (24). However, the extent to
which the insulinotropic activity of GLP-1 is reduced in
patients with type 2 diabetes appears to be less pro-
nounced than the defects found in response to intravenous
glucose (25) and can almost be fully compensated for by
raising GLP-1 plasma concentrations to higher levels (24).
By these means, the hyperglycemia in patients with type 2
diabetes can readily be normalized by the intravenous
administration of GLP-1 (26), even at relatively low doses
(27). Taken together the available evidence, there does not
seem to be a severe impairment in GLP-1 action in patients
with type 2 diabetes. The modest impairments in insulin
release found during GLP-1 administration are most likely
a consequence of the general impairment in -cell function
in patients with type 2 diabetes (2).
For GIP, a marked impairment in the insulinotropic
activity has uniformly been described in all studies adminis-
tering the hormone to patients with type 2 diabetes (23,28–
31). Thus, during hyperglycemic clamp conditions, an
intravenous infusion of GIP in patients with type 2 diabetes
elicited only 46% of the insulin responses found in healthy
control subjects (23). Unlike with GLP-1, this lack of insuli-
notropic efﬁcacy cannot be offset by raising GIP doses even
to highly supra-physiological concentrations (30). Interest-
ingly, the loss of GIP activity seems to be more pronounced
during its continuous infusion than after an intravenous
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the reduction of its insulinotropic activity, infusing GIP to
hyperglycemic patients with type 2 diabetes has no signiﬁ-
cant glucose-lowering effect (33). The lack of glucose-lower-
ing activity of GIP in type 2 diabetes may also partly be
related to its stimulation of glucagon release (34), which
counteracts its residual glucose-lowering actions.
Does the reduction of the incretin effect predispose
the development of type 2 diabetes? To address
whether the diminished incretin effect is a primary, possi-
bly genetically determined, defect predisposing the devel-
opment of type 2 diabetes, we have undertaken a series of
studies in nondiabetic individuals at high risk for the
disease: In initial experiments, ﬁrst-degree relatives of
patients with type 2 diabetes, patients with overt type 2
diabetes, and healthy control subjects were examined with
the intravenous infusion of GIP during a hyperglycemic
clamp experiment (29). Under these conditions, the
amount of insulin released in response to GIP was mark-
edly impaired in the type 2 diabetic patients and interme-
diate in the ﬁrst-degree relatives, suggesting an early
impairment in GIP action in 50% of these individuals.
However, upon further analysis it became obvious that
these ﬁrst-degree relatives also exhibited a similar impair-
ment in insulin secretion after intravenous glucose admin-
istration, thereby suggesting that the reduced insulin
levels found during GIP and glucose co-administration
were secondary to a more general impairment in insulin
secretion rather than a speciﬁc defect in GIP action.
Interestingly, when we tested the effects of GIP administered
as an intravenous bolus at normal fasting glucose levels in a
larger cohort of ﬁrst-degree relatives, we were unable to
detect any impairment in the insulinotropic activity of GIP
(32). Consistent with these ﬁndings, the relative size of the
incretin effect, as well as the secretion of GIP and GLP-1 after
oral glucose ingestion, were completely normal in ﬁrst-
degree relatives (35); furthermore, the same cohort studied
previously did not develop disturbances of oral glucose
tolerance during 4 years of follow-up, as expected for a
high-risk population, and insulin sensitivity in those with a
lesser insulinotropic response to GIP was higher, making the
lower insulin secretory response still adequate for the pre-
vailing degree of insulin resistance (36). Taken together,
these studies did not reveal any evidence for the existence of
a speciﬁc defect in GIP action in ﬁrst-degree relatives of
patients with type 2 diabetes.
Women with a history of gestational diabetes are an-
other group at high risk for developing type 2 diabetes.
Because the typical metabolic abnormalities in these
women may be different from those in the ﬁrst-degree
relatives, we decided to examine the potential distur-
bances in the incretin system in these women as well.
Thus, the group of women included in this study was
predominantly characterized by insulin resistance rather
than by -cell dysfunction (37). Interestingly, there were
no differences in insulin secretion in response to GIP
administered by continuous infusion during a hyperglyce-
mic clamp or as an intravenous bolus in the fasting state
between the women with previous gestational diabetes
and control subjects. Likewise, GLP-1 and GIP levels after
oral glucose ingestion were normal in the women with
previous gestational diabetes (37). Taken together, the
ﬁndings in the ﬁrst-degree relatives of patients with type 2
diabetes and the women with a history of gestational
diabetes seemed to refute the hypothesis that the loss of
GIP activity and the impaired incretin effect in patients
with type 2 diabetes are due to a primary defect predis-
posing the development of the disease (21,38). Rather, the
loss of incretin activity seems to go along with the other
metabolic abnormalities in type 2 diabetes.
In support of this concept, Vilsbøll et al. (39) were able to
demonstrate that a reduced insuliotropic effect of GIP is not
only present in patients with “typical” type 2 diabetes, but
that it can also be found in patients with other types of
diabetes, such as maturity-onset diabetes of the young or
diabetes secondary to pancreatitis. Subsequent studies deter-
mining the percentage contribution of the incretin effect in
such patients were able to conﬁrm these initial ﬁndings (40).
Potential factors responsible for the reduced incre-
tin effect in type 2 diabetes. The importance of the
diminished incretin effect for the dysregulation of post-
prandial glucose control in type 2 diabetes becomes
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FIG. 1. Relationship between the glucose concentrations at fasting (A) and 120 min after the ingestion of 75 g oral glucose (B) and the respective
integrated GLP-1 levels measured over 240 min after oral glucose ingestion in 14 nondiabetic individuals (blue), 17 people with impaired glucose
tolerance or impaired fasting glucose (green), and 17 patients with type 2 diabetes (red). Individual data were taken from ref. 11. r
2 and P values
were calculated by linear regression analyses. NGT, normal glucose tolerance; OGTT, oral glucose tolerance test.
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out of the GIP or GLP-1 receptor as well as from earlier
experiments with GIP immune-neutralization (41–43).
The reasons underlying this phenomenon are less well
established, and three possible factors appear possible:
Diminished maximum insulin secretory capacity.
The incretin effect is deﬁned by the differences in the
insulin secretory responses elicited by oral glucose admin-
istration and intravenous glucose infusion (6,8). Of course,
in terms of -cell stimulation the oral glucose load repre-
sents a much more potent stimulus, because it combines
the insulinotropic effects of circulating glucose, the incre-
tin hormones GIP and GLP-1 (and potentially other ones),
as well as some minor effects of afferent vagal nerves (8).
In contrast, the insulinotropic effect of the intravenous
glucose infusion is restricted to the direct stimulatory
effects of circulating glucose. By these means, comparing
the insulinotropic activity of oral and intravenous glucose
does not only examine the efﬁcacy of the incretin hor-
mones GIP and GLP-1, but it also compares the effects of
a relatively modest activator of insulin release (i.e., hyper-
glycemia) with a relatively potent stimulus of insulin
release (i.e., oral glucose). Given the limited maximum
secretory capacity of the -cells in patients with type 2
diabetes (44), it is obvious that the insulinotropic response
to a larger stimulus would be relatively more impaired that
that of a less potent secretagogue. In other words, the
difference between the insulin responses elicited by a
potent secretagogue and a weaker secretagogue would be
expected to shrink down with diminishing -cell function
(and perhaps mass). Furthermore, the total amount of
glucose administered via the oral route (50 g) typically
exceeds the amount of glucose infused intravenously
(20 g) during isoglycemic clamp experiments. Because
the insulin response to glucose is usually markedly im-
paired in patients with type 2 diabetes, this might further
contribute to the diminished incretin effect in such pa-
tients. On that basis, the diminished incretin effect in
patients with type 2 diabetes may simply reﬂect the
reduced maximum secretory capacity of the -cells in
such patients rather than a speciﬁc problem in incretin
secretion or action. The hypothetical consequences of a
reduction in -cell mass and/or function for the incretin
effect are demonstrated in Fig. 2. Consistent with this
view, we observed a linear inverse relationship between
fasting glucose concentrations and the “size” of the incre-
tin effect (percentage difference in the insulin responses
between oral and intravenous glucose stimulation) in 48
individuals with and without diabetes (Fig. 3). This inter-
pretation is further supported by the ﬁnding that a dimin-
ished incretin effect can also readily be observed in
patients with other types of diabetes (45), and by the fact
that it can be restored through pancreas transplantation in
patients with type 1 diabetes (46). However, further stud-
ies will be required to substantiate this hypothesis.
Reduced GLP-1 secretion. One popular explanation for
the diminished incretin effect in type 2 diabetes has been
a reduction of GLP-1 secretion (47). This hypothesis has
been based on studies demonstrating reductions in meal-
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FIG. 2. Hypothetical impact of a general impairment in -cell function on the incretin effect: In individuals with a normal insulin secretory
capacity, an oral glucose load elicits a much greater insulin secretory response than an intravenous (i.v.) glucose load. With a decreasing -cell
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FIG. 3. Relationship between the relative percentage contribution of
the incretin effect on the overall insulin responses after oral glucose
ingestion and to the respective fasting glucose concentrations in 48
individuals with and without diabetes. Individual data were taken from
refs. 35 and 7. The solid line denotes the regression line calculated by
regression analyses in relation to the upper and lower 95% CIs.
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ing type 2 diabetes and subjects with impaired glucose
tolerance (10,16,17). However, because the timing of the
impairments in GLP-1 concentrations (2–4 h after meal
ingestion) does not coincide with the typical defects in
meal-induced insulin release (30–60 min after meal
ingestion), such impairment in GLP-1 release cannot plau-
sibly explain the loss of incretin activity in patients with
type 2 diabetes. Furthermore, the majority of studies in
patients with type 2 diabetes have failed to show similar
impairments in GLP-1 concentrations (18), suggesting that
in the vast majority of diabetic patients defects in GLP-1
release do not explain the diminished incretin effect. It is,
however, possible that changes in the level of glycemia
have an impact on the individual GIP and GLP-1 responses
after meal ingestion. Along these lines, the postprandial
concentrations of GIP and GLP-1 were found signiﬁcantly
lower during hyperglycemic clamp conditions compared
with euglycemia, probably driven by a glucose-induced
delay in gastric emptying (48). It is therefore conceivable
that acute elevations in circulating glucose levels may
partly blunt postprandial incretin responses. By this rea-
soning, the increased GLP-1 levels that have been reported
after the administration of metformin may simply be due
to the glucose-lowering effect of the drug (49). However,
even though hyperglycemia appears to acutely lower
GLP-1 secretion, it is completely unclear whether chronic
hyperglycemia has a negative impact on GLP-1 levels as
well. Correlation analyses did not reveal a signiﬁcant
association between fasting or postchallenge glucose con-
centrations and GLP-1 release (Fig. 1). Taken together,
changes in GLP-1 secretion may occur under different
conditions, but a general reduction in GLP-1 release fails
to explain the reduced incretin effect in type 2 diabetes.
Speciﬁc loss of GIP activity. A number of studies have
compared the insulinotropic effect of GIP in patients with
type 2 diabetes and healthy control subjects. Uniformly, a
relative reduction of GIP activity has been described in
these studies (23,28–31). However, while this may cer-
tainly suggest a defect in GIP signaling, one should not
forget that the efﬁcacy of other secretagogues, especially
glucose, is also severely impaired in these patients
(3,44,50). Thus, in a direct comparison between patients
with type 2 diabetes and healthy control subjects, the
insulinotropic effect of an intravenous glucose bolus was
found to be reduced by 85% in the diabetic patients (51),
and other studies have clearly shown a reduction in
ﬁrst-phase insulin release in response to glucose with
increasing fasting glucose levels (52). The magnitude of
the impairment in glucose-induced insulin secretion there-
fore seems to be comparable to the respective defect in
GIP-induced insulin secretion described in other studies
(23,30). To address this point, we have correlated the
insulin secretory responses to GIP administration with the
respective responses to intravenous glucose administra-
tion in a large group of individuals (n  77), including
patients with type 2 diabetes, ﬁrst-degree relatives of
patients with type 2 diabetes, women with a history of
gestational diabetes, and healthy subjects (Fig. 4). Indeed,
there was a tight correlation between the insulin re-
sponses to GIP and to glucose administration in these
studies, consistent with the idea that the impairment in
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FIG. 4. A: Relationship between the plasma insulin levels during the intravenous (i.v.) administration of glucose alone and the insulin levels
during the combined administration of i.v. glucose and GIP in 27 healthy control subjects, 27 ﬁrst-degree relatives of patients with type 2
diabetes, 13 women with previous gestational diabetes, and 10 patients with type 2 diabetes. Individual data were taken from refs. 29, 35, and
37. B: Relationship between the plasma insulin levels during the intravenous administration of GIP and glucose and the insulin levels measured
30 min after oral ingestion of 75 g glucose in 54 healthy control subjects, 44 ﬁrst-degree relatives of patients with type 2 diabetes, and 20 women
with previous gestational diabetes. Individual data were taken from refs. 32 and 37. The solid line denotes the regression line calculated by
regression analyses in relation to the upper and lower 95% CIs.
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glucose-induced insulin secretion. A less close relation-
ship was observed between the insulin release elicited by
the intravenous bolus administration of GIP at normal
fasting glucose levels and the insulin concentrations 30
min after oral glucose ingestion (Fig. 4). Given that GIP
acts in concert with glucose to enhance insulin secretion
(Fig. 5), it is possible that the inability of GIP to augment
insulin secretion during hyperglycemia is primarily due to
the lack of glucose-potentiation of insulin release in pa-
tients with diabetes. However, while such an argument
may seem to plausibly explain the loss of GIP action in
patients with type 2 diabetes, one striking phenomenon
still remains unexplained: Why does GLP-1 still potently
stimulate insulin release during hyperglycemia in patients
with type 2 diabetes? Possibly, the unequal insulinotropic
efﬁcacy of GIP and GLP-1 in patients with type 2 diabetes
is due to an additional (and yet unexplored) mechanism of
action rather than due to a speciﬁc defect in GIP signaling.
In fact, both GIP and GLP-1 have been shown to exert their
actions through binding to G-protein–coupled receptors
on the -cells, activation of adenylate cyclase, and subse-
quent cAMP generation (53). In addition, PI 3-kinase
activation has been reported for both GIP and GLP-1.
However, while these downstream signaling mechanisms
are rather similar for both incretin hormones, recent
studies have suggested a preferential upregulation of
insulin receptor substrate 2 (IRS-2) through epidermal
growth factor receptor activation by GLP-1 (54). This and
other yet unexplored mechanisms may therefore contrib-
ute to the unequal efﬁcacy of GIP and GLP-1 in patients
with type 2 diabetes.
Working models for the loss of GIP activity in type 2
diabetes. Assuming that a speciﬁc problem in GIP signal-
ing in patients with type 2 diabetes does indeed exist, the
obvious question arising is: What are the reasons underly-
ing such defect? In fact, the loss of insulinotropic GIP
effects in type 2 diabetes despite the relatively well pre-
served activity of GLP-1 is quite surprising because both
incretins are structurally similar, are released under al-
most identical conditions, and share similar signaling
pathways inside the -cell (53,55). Thus, both hormones
bind to similar but distinct seven–membrane spanning
G-protein–coupled surface receptors leading to intracellu-
lar cAMP generation and intracellular calcium release
(53,55). However, this does not exclude alterations in the
function or quantitative expression of the GIP receptor in
patients with type 2 diabetes (56).
Considering the loss of GIP efﬁcacy in type 2 diabetes in
light of the available evidence from clinical studies as well
as from animal and tissue culture based experiments, two
different working models seem to arise:
Genetic defects in GIP signaling. The lack of GIP effect
in type 2 diabetes has given rise to try and link polymor-
phisms in the GIP receptor with the type 2 diabetic
phenotype. Two earlier studies from Europe and Japan
have failed to establish an association between type 2
diabetes and GIP receptor polymorphisms (57,58). A more
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not GIP in carriers of the T allele of rs7903146 TCF7L2
(59). Likewise, Scha ¨fer and colleagues found a reduced
insulinotropic effect of GLP-1 in carriers of the rs10010131
polymorphism of the WFS1 gene (60) as well as in carriers
of TCF7L2 polymorphisms (61). These studies therefore
suggest that genetic alterations in GLP-1 action may play a
role in type 2 diabetes (62), which is surprising, given the
relatively well preserved efﬁcacy of GLP-1 in such patients
(23). However, a genetic defect in GIP action predisposing
to type 2 diabetes has not yet been established. Clearly,
further studies in this area will be required.
Down-regulation/desensitization of the GIP recep-
tor in response to hyperglycemia. The idea of a
reduced expression of GIP receptors in patients with type
2 diabetes has already been expounded in 1997 (56), but
until now no data regarding GIP receptor expression on
islets from humans with and without type 2 diabetes have
become available, owing to the limited accessibility of
human pancreatic tissue. However, a couple of experimen-
tal studies have lent support to this concept: Lynn et al.
(63) found reduced GIP receptor mRNA and protein levels
in islets from Vancouver diabetic fatty rats, suggesting an
impaired receptor expression in response to hyperglyce-
mia. Subsequent experiments from the same group found
a down-regulation of the GIP receptor in a transfected
-cell line (INS-cells) (64). More recently, Xu et al. (65)
found reduced GIP mRNA levels in hyperglycemic rats
after a 90% partial pancreatectomy. Interestingly, these
effects could be reversed by glucose-normalization using
phlorizin treatment. However, in the same study the ex-
pression of the GLP-1 receptor was regulated by hypergly-
cemia in a similar manner (65), which is rather
inconsistent with the clinical ﬁndings on GIP and GLP-1
efﬁcacy in patients with type 2 diabetes (23). In addition to
this downregulation of the GIP receptor in response to
hyperglycemia, a desensitization of the GIP receptor in
response to chronically elevated GIP concentrations has
also been described in GIP receptor–transfected cell lines
(66). However, since elevations in GIP plasma concentra-
tions are not a typical ﬁnding in most patients with type 2
diabetes (67), this mechanism is less likely to contribute to
the impairment of GIP efﬁcacy in type 2 diabetes.
To examine the impact of chronic hyperglycemia on
GIP-induced insulin release, we have compared the rela-
tive stimulation of insulin secretion during the intravenous
administration of GIP at hyperglycemic clamp conditions
in a total of 93 individuals with the respective fasting
glucose concentrations at the day of the experiment (Fig.
6). The insulin responses to GIP were found relatively
normal in the individuals presenting with fasting glucose
concentrations of less than 100 mg/dl. However, as
glucose concentrations exceeded this level, there was a
progressive decline in GIP activity on insulin secretion,
with an almost complete loss of efﬁcacy in patients with
overt hyperglycemia of 150–250 mg/dl. Thus, even though
the association between the insulinotropic effect of GIP
and the respective fasting glucose levels cannot serve to
prove any causality, these analyses are very consistent
with the concept of a GIP receptor downregulation in
response to high glucose concentrations. The potential
factors contributing to the diminished incretin effect in
type 2 diabetes have been summarized as a working model
in Fig. 7.
Can the incretin effect be restored by normalizing
hyperglycemia? Assuming that the relative impairment of
the incretin effect and the loss of GIP activity in patients
with type 2 diabetes are secondary to the chronic hyper-
glycemia, the clinical implication would be that normaliz-
ing the hyperglycemia in these patients should also restore
the insulinotropic effect of GIP. Højberg and colleagues
(68–70) set out to address this point by subjecting eight
patients with type 2 diabetes in poor glycemic control
(A1C levels 8.6  1.3%) to a 4-week intensive insulin
treatment with the aim of completely normalizing glyce-
mia in these patients. The insulin responses to GIP and
GLP-1 were determined before and after the intervention
during a hyperglycemic clamp experiment. There was
indeed a signiﬁcant improvement in insulin secretion in
response to both GIP and GLP-1 after glucose lowering
(68), whereas no effects were found with regards to the
secretion of both hormones after meal ingestion (69).
However, a complete regain of GIP activity to the levels
found in healthy subjects was not accomplished in this
study (68). Furthermore, the observed improvements in
insulin secretion were not speciﬁc to the actions of GIP
but also affected the insulinotropic effect of GLP-1 as well
as the overall -cell responses to meal ingestion (69). It is
therefore difﬁcult to fully ascribe these phenomena to the
reversal of a speciﬁc defect in incretin signaling. In fact, a
number of previous studies have demonstrated that low-
ering hyperglycemia in patients with type 2 diabetes can
also lead to marked improvements of insulin secretion in
response to intravenous glucose and other secretagogues,
probably mediated by the mechanism of -cell rest (71–
73). In addition, although glucose control was signiﬁcantly
improved by the insulin treatment in this study, complete
normoglycaemia was not achieved in these patients at the
end of the study (mean glucose concentrations 7.4 mmol/l
[133 mg/dl]) (68). Based on the analyses of our studies
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FIG. 6. Relationship between the relative increase in insulin secretion
during the intravenous administration of GIP at hyperglycemic clamp
conditions and the respective fasting glucose concentrations in 93
individuals with and without diabetes. The relative increments in
insulin secretion were expressed in relation to the mean values
obtained in the individuals with normal glucose concentrations (fast-
ing glucose levels <100 mg/dl). Individual data were taken from refs.
29, 30, and 35. The solid line denotes the regression line calculated by
nonlinear regression analyses using an exponential decay function.
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activity of GIP were still severely impaired in individuals
with similar fasting glucose concentrations. Nevertheless,
the studies by Madsbad and Højberg clearly demonstrate
that reducing the hyperglycemia in patients with type 2
diabetes can also elicit signiﬁcant improvements in the
incretin effect.
Conclusions and outlook. The diminished incretin ef-
fect in patients with type 2 diabetes was described more
than 20 years ago (5), but even now the underlying
causes remain elusive. Although a couple of studies
have described alterations in the postprandial concen-
trations of GIP and GLP-1, there is little evidence to
suggest that impairments in incretin secretion play a
major role in the pathogenesis of type 2 diabetes (21).
The insulinotropic action of the incretin hormones is
clearly impaired in patients with type 2 diabetes, with
GLP-1 retaining signiﬁcantly more efﬁcacy than GIP
(23). However, the magnitude of the reduction in GIP
efﬁcacy in patients with type 2 diabetes appears to be
comparable to the impairment in glucose-induced insu-
lin secretion in such patients, suggesting that the im-
paired GIP-induced insulin secretion may largely be
secondary to of a general impairment in -cell function.
In addition, there is evidence from preclinical and
clinical studies that hyperglycemia further reduces the
insulinotropic effect of GIP, possibly through downregu-
lation of the GIP receptor (63). Ultimately, the dimin-
ished incretin effect in patients with type 2 diabetes may
be a consequence of the inability of the -cells to
provide an appropriate secretory response to a large
stimulus (i.e., oral glucose), whereas a smaller stimulus
(i.e., intravenous glucose) may still elicit a relatively
normal insulin response (Fig. 2). On the basis of such
reasoning, the reduction of the incretin effect in patients
with diabetes may simply be an epi-phenomenon of
chronic hyperglycemia, independent of any primary
defect in GIP or GLP-1 action. Reducing hyperglycemia
and enhancing -cell function in general terms may
therefore also improve the incretin effect, independent
of speciﬁc interventions related to circulating levels of
GIP or GLP-1.
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FIG. 7. Working model for the diminished incretin effect in type 2 diabetes: The reduction in -cell mass (A) leads to a signiﬁcant impairment in
the maximum insulin secretory capacity of the -cells (D). The reduced secretory capacity leads to a preferential impairment of the relative
insulin response to oral glucose, whereas a relatively normal insulin response to intravenous glucose (a comparably weaker -cell stimulus) can
still be maintained. The defects in -cell function and the impaired incretin effect (B) lead to chronic hyperglycemia (E), which may diminish
GLP-1 secretion (F) and impair GIP action through GIP-receptor downregulation (C), thereby further diminishing the incretin effect. Genetic
factors may independently modify -cell mass and function as well as GLP-1 secretion. Dashed lines in D, E, and F indicate the respective patterns
typical of patients with type 2 diabetes, solid lines show the respective normal patterns. The dashed line in B illustrates the insulin levels after
oral glucose ingestion; the solid line shows the respective patterns after isoglycemic intravenous glucose administration.
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